Cranial nerve involvement in infratentorial progressive multifocal leukoencephalopathy
Citation Manager Formats
Make Comment
See Comments

Abstract
Neurology® 2012;79:104–105
A 71-year-old man presented with right hypoacusis following immunosuppressive therapy after liver transplantation.
MRI demonstrated T1-hypointense and T2-hyperintense white matter lesions involving the right middle cerebellar peduncle, adjacent pons, and cerebellum, consistent with progressive multifocal leukoencephalopathy (PML), confirmed with PCR in a CSF sample. Fluid-attenuated inversion recovery and double inversion recovery sequences revealed involvement of right cranial nerves V and VIII (figure).
The lesion showed hyperintensity on T2-weighted sequence (A) without mass effect (arrows). Both fluid-attenuated inversion recovery (B, C) and double inversion recovery (D) sequences confirmed the additional involvement of right cranial nerves V (arrowhead) and VIII (arrow).
CSF revealed normal cell counts, glucose, and protein. PCR for herpesviruses and toxoplasmosis and CSF culture for Mycobacterium tuberculosis, Listeria monocytogenes, and Cryptococcus neoformans were negative. Chest and abdominal CT were normal.
In PML, infratentorial white matter is a common area of involvement.1,2 Our patient suggests cranial nerve involvement is possible.
Footnotes
Dr. Hodel reports no disclosures. Dr. Outteryck has received funding for travel from Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Teva Pharmaceutical Industries Ltd, and Sanofi-Aventis and for speaker honoraria from Bayer Schering Pharma, Biogen Idec and Sanofi-Aventis. Dr. Zéphir has received funding for travel from Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Teva Pharmaceutical Industries Ltd, and Sanofi-Aventis and for speaker honoraria from Bayer Schering Pharma, Biogen Idec, Teva Pharmaceutical Industries Ltd, and Sanofi-Aventis. Dr. Rodallec and Dr. Zins report no disclosures. Dr. Vermersch serves on scientific advisory board for Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Teva Pharmaceutical Industries Ltd, Almirall, and Sanofi-Aventis; has received funding for travel and speaker honoraria from Biogen Idec, Bayer Schering Pharma, Novartis, Teva Pharmaceutical Industries Ltd, Sanofi-Aventis, and Merck Serono; and receives research support from Biogen Idec, Merck Serono, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd, and Bayer Schering Pharma. Dr. Leclerc reports no disclosures. Go to Neurology.org for full disclosures.
Author contributions: Dr. Hodel: drafting/revising the manuscript, analysis or interpretation of data, acquisition of data. Dr. Outteryck: drafting/revising the manuscript, study concept or design, analysis or interpretation of data. Dr. Zéphir: drafting/revising the manuscript. Dr. Rodallec: drafting/revising the manuscript, analysis or interpretation of data, study supervision. Dr. Zins: drafting/revising the manuscript. Dr. Vermersch: drafting/revising the manuscript, analysis or interpretation of data, acquisition of data. Dr. Leclerc: drafting/revising the manuscript, analysis or interpretation of data.
- Copyright © 2012 by AAN Enterprises, Inc.
References
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis
Dr. Robert Pitceathly and Dr. William Macken
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Punctate patternA promising imaging marker for the diagnosis of natalizumab-associated PMLJérôme Hodel, Christine Darchis, Olivier Outteryck et al.Neurology, March 23, 2016 -
Resident & Fellow Section
Clinical Reasoning: A man with rapidly progressive weakness and respiratory failureDenise Xu, Kathleen Murphy, Ramani Balu et al.Neurology, August 13, 2018 -
Resident & Fellow Section
Clinical Reasoning: A 71-Year-Old Man With Horizontal Gaze Palsy, Anarthria, and QuadriparesisIkreet Cheema, Nicole Ng, Tychicus Chen et al.Neurology, April 14, 2021 -
Case
HIV-associated PML may appear inflammatory because of higher CD4 countJoy Zhuo Ding, Ryan Gotfrit, Carlos Torres et al.Neurology: Clinical Practice, March 26, 2019